IQVIA gains as R&D Solutions drive Q3 beat

What happened

IQVIA reported third-quarter revenue of $4.4B, about 8% higher than a year earlier, beating the consensus by $60M. R&D Solutions revenue rose 9% to $2.6B, and IQVIA raised its full-year revenue outlook to $17.35B-$17.50B.

Confirmed

Global impact / market context

Stronger R&D Solutions revenue shows drug developers are still paying IQVIA for outsourced research work, which supports future sales and profit. The raised outlook signals management expects that demand to continue, which matters to investors valuing the shares.

Analyst inference

The article names ICON, Charles River Laboratories, Fortrea, and Medpace as peers, and says Medpace also beat expectations. That suggests demand for outsourced research is holding up across the industry, a read-across for investors holding competitor shares.

Analyst inference

What to watch

1. IQVIA raised full-year revenue guidance to $17.35B-$17.50B and adjusted earnings per share to $12.90-$13.00, which is profit per share after certain adjustments. Confirmed
2. Watch whether the raised outlook is matched by continued R&D Solutions growth, since that segment drove the quarterly beat and supports the company's expected revenue. Proposed
3. Watch peer results from ICON, Charles River Laboratories, Fortrea, and Medpace for signs that outsourced research demand is broadly strong rather than specific to IQVIA. Analyst inference

Evidence

• seekingalpha.com